699,535 Shares in GW Pharmaceuticals PLC (GWPH) Purchased by Janus Henderson Group PLC

Janus Henderson Group PLC purchased a new position in shares of GW Pharmaceuticals PLC (NASDAQ:GWPH) in the second quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 699,535 shares of the biopharmaceutical company’s stock, valued at approximately $70,128,000. Janus Henderson Group PLC owned about 2.76% of GW Pharmaceuticals PLC as of its most recent SEC filing.

A number of other large investors have also recently added to or reduced their stakes in GWPH. Royal Bank of Canada boosted its holdings in shares of GW Pharmaceuticals PLC by 0.4% in the 2nd quarter. Royal Bank of Canada now owns 4,240 shares of the biopharmaceutical company’s stock valued at $424,000 after buying an additional 18 shares during the last quarter. Capital World Investors boosted its holdings in shares of GW Pharmaceuticals PLC by 6.3% in the 2nd quarter. Capital World Investors now owns 675,800 shares of the biopharmaceutical company’s stock valued at $67,749,000 after buying an additional 40,000 shares during the last quarter. Goldman Sachs Group Inc. boosted its holdings in shares of GW Pharmaceuticals PLC by 48.3% in the 2nd quarter. Goldman Sachs Group Inc. now owns 48,559 shares of the biopharmaceutical company’s stock valued at $4,868,000 after buying an additional 15,816 shares during the last quarter. Employees Retirement System of Texas acquired a new stake in shares of GW Pharmaceuticals PLC in the 2nd quarter valued at approximately $5,313,000. Finally, HighTower Advisors LLC boosted its holdings in shares of GW Pharmaceuticals PLC by 40.2% in the 2nd quarter. HighTower Advisors LLC now owns 2,865 shares of the biopharmaceutical company’s stock valued at $290,000 after buying an additional 821 shares during the last quarter. 75.07% of the stock is owned by hedge funds and other institutional investors.

GW Pharmaceuticals PLC (NASDAQ:GWPH) last posted its quarterly earnings data on Monday, August 7th. The biopharmaceutical company reported ($2.07) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.73) by ($0.34). GW Pharmaceuticals PLC had a negative return on equity of 28.80% and a negative net margin of 1,384.41%. The business had revenue of $3.14 million during the quarter, compared to analysts’ expectations of $2.10 million. During the same period in the prior year, the firm posted ($0.05) EPS.

GWPH has been the subject of several recent analyst reports. Zacks Investment Research downgraded GW Pharmaceuticals PLC from a “hold” rating to a “sell” rating in a report on Thursday, July 6th. BidaskClub raised GW Pharmaceuticals PLC from a “sell” rating to a “hold” rating in a report on Wednesday, June 21st. ValuEngine raised GW Pharmaceuticals PLC from a “sell” rating to a “hold” rating in a report on Wednesday, June 21st. Leerink Swann reissued an “outperform” rating and issued a $153.00 price objective (down previously from $160.00) on shares of GW Pharmaceuticals PLC in a report on Monday, October 2nd. Finally, Evercore ISI initiated coverage on GW Pharmaceuticals PLC in a report on Wednesday, August 16th. They issued an “outperform” rating and a $154.00 price objective for the company. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating, five have issued a buy rating and one has given a strong buy rating to the stock. GW Pharmaceuticals PLC has a consensus rating of “Buy” and a consensus price target of $143.05.

COPYRIGHT VIOLATION NOTICE: “699,535 Shares in GW Pharmaceuticals PLC (GWPH) Purchased by Janus Henderson Group PLC” was reported by Ticker Report and is owned by of Ticker Report. If you are viewing this story on another publication, it was illegally copied and republished in violation of U.S. & international copyright & trademark law. The legal version of this story can be viewed at https://www.tickerreport.com/banking-finance/2957322/699535-shares-in-gw-pharmaceuticals-plc-gwph-purchased-by-janus-henderson-group-plc.html.

GW Pharmaceuticals PLC Profile

GW Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing therapeutics from its cannabinoid product platform in a range of disease areas. The Company’s lead cannabinoid product candidate is Epidiolex, which is a liquid formulation of pure plant-derived cannabidiol (CBD).

Institutional Ownership by Quarter for GW Pharmaceuticals PLC (NASDAQ:GWPH)

Receive News & Ratings for GW Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals PLC and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


Leave a Reply

© 2006-2017 Ticker Report. Google+.